• Perumallu Sudarsanam Department of Pharmaceutics, Seshachala College of Pharmacy, Tirupathi - Chennai High way, Puttur-517 583, Chittoor (dist), Andhra Pradesh, India
  • Balakrishanan M Department of Pharmacognosy, Seshachala College of Pharmacy, Tirupathi - Chennai High way, Puttur-517 583, Chittoor (dist), Andhra Pradesh, India
  • VaddiReddy Sireesha Department of Pharmaceutics, Ratnam Institute of Pharmacy, Pidthapolur (V), Muthkur (M), Nellore-524346, Andhra Pradesh, India
  • Kommi Saritha Department of Pharmaceutics, Ratnam Institute of Pharmacy, Pidthapolur (V), Muthkur (M), Nellore-524346, Andhra Pradesh, India


Piroxicam, Delay release, FTIR, Prostaglandins


The present investigation of Piroxicam delayed release tablets, many research studies have completed the solution of above mentioned Non steroidal anti inflammatory drug one technology among of all to provide drug with enteric coated polymers so delay release and make release of drug in proximal small intestine. The sugar spheres will be taken into a FBP and drug will be coated onto the spheres and then they will be sub coated and enteric coated. The enteric coated pellets will be compressed into tablets by direct compression. The tablets will be prepared by using sugar spheres HPMC3cps, HPMC5cps, EL30D5, GMS, TEC etc. The prepared tablet will be coated by using pink and various parameters evaluated as per standard procedure.  The FTIR studies will be conducted for optimized formula to prove that the formulas will no incompatibility between the drug and excipients. The drug release profile will be compared with the innovator, formulation has shown similar results, and it was said to be optimized of all formulations. Piroxicam is mainly used to reduce pain, swelling, and joint stiffness from arthritis. Reducing these symptoms helps you do more of your normal daily activities. They work by reducing the levels of prostaglandins, chemicals that are responsible for pain, fever, and inflammation. Piroxicam blocks the enzyme that makes prostaglandins, resulting in lower concentrations of prostaglandins in body.


Download data is not yet available.


Thomas N. Tozer, Malcolm Rowland. Introduction to pharmacokinetics and pharmacodynamics: Ed-4: 119: 2006.

Thomas W.Y.L., Robinson J. The Science and Practice of Pharmacy, Lippinkette, William and Willins: 20th ed: 903-911: 2005.

Follonier N., Doelker E., Biopharmaceutical comparasion of oral multiple-unit and single unit sustained release dosage forms. STP Pharma Sciences.2: 141-145: 1992.

Vial-Bernasconi A. C., Doelker E., Buri P., Prolonged release capsules divided and monolithic forms. STP Pharma Sciences. 4:397-409: 1988.

Ghebre-Sellassie, I. Pellets: A General Overview. In: Ghebre-Sellassie, Pharmaceutical Pelletization Technology. Marcel Dekker, New York: Ed- I: 1-13: 1989.

Kleinebudde P., Knop K. Direct pelletization of pharmaceutical pellets in fluid bed processes. In: Seville, J. P. K. Granulation. Elsevier: vol-15: 780-811: 2007.

Kristensen J. Granulation - review of wet granulation. Drug Development and Industrial Pharmacy: Ed-5:13: 1987.

Rashid H. A., Heinamaki J. Z., Antikainen O., Zilruusi J. Effects of process variables on the size, shape and surface characteristics of microcrystalline cellulose beads prepared in a centrifugal granulator. Drug Development and Industrial Pharmacy., vol-25: 605: 1999.

Liew V. C., Wan C. S. L., Heng P. W. S. Role of base plate rotational speed in controlling spheroid size distribution and minimizing oversize particle formation during spheroid production by rotary processing. Drug Development and Industrial Pharmacy vol-26: 953 -963:2000.

Vertommen Internal and external structure of pellets made in a rotary processor. International Journal of Pharmaceutics., vol-146:21 – 29: 1996.

Holm P., Bonde M., Wigmore T. Pelletization by granulation in a rotary processor RP-2. Part 1. Effects of process and product variables on granule growth. Pharmaceutical Technology Europe vol-8: 22 – 36: 1996.

Paterakis P. G., Korakianiti E. S., Dallas P. P., Rekkas D. M. Evaluation and simultaneous optimization of some pellets characteristics using a 33 factorial design and the desirability function. International Journal of Pharmaceutics vol-248: 51-60: 2002.

Moji Chistianah Adeyeye, Harry G. Brittain. Preformulation in Solid dosage form development: vol-19: 653-671: 1993.

James W. Mc Ginity, Linda A. felton. Aqueous polymeric coating for pharmaceutical dosage forms: vol- 12: 191: 2002.

Svetlana Ibric, Milica Jovanovic , Zorica Djuric, Jelena Parojcic, Slobodan D. Petrovic, Ljiljana Solomun, Biljana Stupar, artificial neural networks in the modeling and optimization of aspirin extended release tablets with eudragit l 100 as matrix substance AAPS PharmSciTech 1-9: 2003.


78 Views | 86 Downloads

How to Cite

Perumallu Sudarsanam, Balakrishanan M, VaddiReddy Sireesha, and Kommi Saritha. “FORMULATION AND EVALUATION OF PIROXICAM DELAYED RELEASE TABLETS”. International Journal of Pharmaceutics and Drug Analysis, vol. 4, no. 6, June 2016, pp. 318-2,



Research Articles
Share |